Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal

Espejo-Cruz, María Lola; González-Rubio, Sandra; Olaya, Javier Manuel Zamora; Amado, Víctor; Alejandre, Rafael; Sánchez-Frías, Marina; Ciria, Rubén; Mata, Manuel de la; Rodríguez‐Perálvarez, Manuel; Ferrín, Gustavo

doi:10.3390/ijms222313073

Cited by 14 publications

(20 citation statements)

References 154 publications

(243 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HCC patients with high number of CTCs need more careful surveillance in early interventions ( 44 ). EpCAM-based enrichment methods are not able to be used in the enrichment of CTCs which express low level of EpCAM ( 95 ) or lose expression of EpCAM during the process of EMT ( 96 , 97 ).…”

Section: Biomarkers Of Ctcs In Hccmentioning

confidence: 99%

Clinical applications of circulating tumor cells in hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a highly malignant tumor and ranked as the fourth cause of cancer-related mortality. The poor clinical prognosis is due to an advanced stage and resistance to systemic treatment. There are no obvious clinical symptoms in the early stage and the early diagnosis rate remains low. Novel effective biomarkers are important for early diagnosis and tumor surveillance to improve the survival of HCC patients. Circulating tumor cells (CTCs) are cancer cells shed from primary or metastatic tumor and extravasate into the blood system. The number of CTCs is closely related to the metastasis of various solid tumors. CTCs escape from blood vessels and settle in target organs, then form micro-metastasis. Epithelial-mesenchymal transformation (EMT) plays a crucial role in distant metastasis, which confers strong invasiveness to CTCs. The fact that CTCs can provide complete cellular biological information, which allows CTCs to be one of the most promising liquid biopsy targets. Recent studies have shown that CTCs are good candidates for early diagnosis, prognosis evaluation of metastasis or recurrence, and even a potential therapeutic target in patients with HCC. It is a new indicator for clinical application in the future. In this review, we introduce the enrichment methods and mechanisms of CTCs, and focus on clinical application in patients with HCC.

show abstract

Section: Biomarkers Of Ctcs In Hccmentioning

confidence: 99%

Clinical applications of circulating tumor cells in hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 57 GPC3 expression is more commonly detected in moderately to poorly differentiated HCC tumor cells, which could facilitate extrahepatic migration; moreover, the presence of GPC3+ CTCs suggests metastatic HCC. 58 ASGPR is a transmembrane protein expressed only on the surface of liver cells, and is highly expressed in well-differentiated HCC. EpCAM is one of the most commonly used membrane-associated proteins for capturing CTCs.…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

“…The expression of EMT markers such as vimentin, twist, zinc finger E-box-binding (ZEB)1, ZEB2, snail, slug, and E-cadherin has been studied in liver-derived CTCs from HCC patients. 58 In the study by Cheng, 61 the CanPatrol TM system was used to stratify CTCs into three phenotypic subgroups according to the predominantly expressed markers: epithelial phenotype (EpCAM, CK8/18/19), mesenchymal phenotype (vimentin, twist), and mixed phenotype. Total CTCs had a superior diagnostic value over AFP in differentiating HCC from nonmalignant liver disease among 176 patients.…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

“…The marker GPC3 is a cell membrane-anchored protein used in the clinic for HCC pathological analysis and characterization 57. GPC3 expression is more commonly detected in moderately to poorly differentiated HCC tumor cells, which could facilitate extrahepatic migration; moreover, the presence of GPC3+ CTCs suggests metastatic HCC 58. ASGPR is a transmembrane protein expressed only on the surface of liver cells, and is highly expressed in well-differentiated HCC.Cancer Management and Research 2022:14 https://doi.org/10.2147/CMAR.S373165 DovePress 2739 Dovepress…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma

Ding¹,

Zhao²

2022

CMAR

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system and has a 5-year overall survival rate of 14.1%. Many HCC patients are diagnosed at an advanced stage, and thus early screening is essential for reducing the mortality of HCC. In addition to commonly used detection indicators such as serum alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) and abnormal prothrombin (protein induced by vitamin K absence II, PIVKA-II), liquid biopsy techniques have been demonstrated to have diagnostic value in HCC detection. Compared with invasive procedures, liquid biopsy can detect circulatory metabolites of malignant neoplasms. Liquid biopsy techniques can detect circulating tumor cells, circulating tumor DNA, circulating RNA and exosomes and have been used in the early screening, diagnosis and prognostic evaluation of HCC. This paper reviews the molecular biological characteristics and application of different liquid biopsy techniques, and aim to highlight promising biomarkers that may be feasible options for early-stage HCC evaluation to improve early screening in populations at high risk for HCC.

show abstract

“…clinical treatment [3]. Liquid biopsy, particularly circulating tumor cells (CTCs), has emerged as a useful tool for the diagnosis and monitoring of therapeutic responses in different tumors [4,5].…”

mentioning

confidence: 99%

Association between BRAF expression in circulating tumor cells and the clinical feature of patients with multiple myeloma

Tang¹,

Zhang²,

Zhou³

et al. 2022

neo

View full text Add to dashboard Cite

Multiple myeloma (MM) is the most common hematological malignancy with uncontrolled proliferation of monoclonal plasma cells. Despite treatment improvements, MM remains an incurable disease for most patients. Therefore, promising molecular markers are required for MM treatment decisions. In the present study, we explored the relationship between the BRAF expression in circulating tumor cells (CTCs) and the clinical features of patients with MM. The results showed that CTCs were associated with MM staging, and the expression of BRAF was associated with different blood cells, blood albumin levels, and Eastern Cooperative Oncology Group (ECOG) score. BRAF expression positively correlated with total CTCs, hybrid CTCs, and mesenchymal CTCs. Taken together, CTCs tightly correlated with the clinical stages and characteristics of MM. Our findings may provide a promising prognosis biomarker for MM treatment decisions.

show abstract

Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal

Cited by 14 publications

References 154 publications

Clinical applications of circulating tumor cells in hepatocellular carcinoma

Clinical applications of circulating tumor cells in hepatocellular carcinoma

The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma

Association between BRAF expression in circulating tumor cells and the clinical feature of patients with multiple myeloma

Contact Info

Product

Resources

About